Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs neostigmine for postoperative pulmonary complications after VATS lobectomy in patients with impaired lung function
ChiCTR2200056585Phase 4Not yet recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Feb 2022
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in postoperative respiratory complications (PRC) (2 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Postoperative pulmonary complications. Planned start Feb 2022; status: not yet recruiting.
02
Drugs
Sugammadex
03
Conditions
postoperative respiratory complications (PRC)
Beyond the preview
Go deeper on ChiCTR2200056585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056585.